Pharmalot recently caught up with Mike Mason, head of Eli Lilly’s diabetes branch, to discuss the drugmaker’s generic alternative to its Humalog insulin, LisPro.
Lilly offers LisPro at half the price of Humalog, $137.35 per vial.
While two senators in December issued a report suggesting the program failed, Lilly’s CEO, David Ricks, said the findings were “nonsense.”
To read the discussion on STAT, click here. (Paid subscription required)